Search
Memorial Sloan Kettering Cancer Center (MSK) today celebrates its 26th year of the "holiday hallway." Each year during December, MSK’s carpenters, toolmakers, locksmiths, electricians, and painters construct a winter wonderland in the basement hallway of MSK for patients, families, and staff to visit and enjoy. The decades-long tradition brings joy and cheer to all and has grown in size and detail year after year. The “holiday hallway” is a labor of love for MSK’s Facilities staff, who give of themselves to create the magical MSK tradition.
Learn about magnesium's essential role in overall health and in cancer treatment and prevention. Dr. Urvi Shah answers questions about diet, supplements, and what the research shows.
Researchers from MSK presented promising studies on treating rare solid tumors including mesothelioma and three types of soft-tissue at the annual meeting of the American Society of Clinical Oncology.
Learn how a new treatment approach using high-dose radiation has given hope to people with inoperable tumors.
Meet Dario Cortes, who was treated for rectal cancer at Memorial Sloan Kettering and is now back to doing the activities he loves.
Conozca a Dario Cortes, que recibió tratamiento para el cáncer rectal en el Memorial Sloan Kettering y ahora hace las actividades que ama.
In a proof-of-concept study, researchers at MSK and the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone’s cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells.
The research identifies a protein called ENPP1 as a potential drug target in the treatment of advanced cancers with chromosome instability.
On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.
Several Memorial Sloan Kettering investigators are focused on the study of bacteria, which can teach us much about human health, and about cancer in particular.